SLC25A31 Variant 1: Potential Therapeutic Target for Neurotransmitter Disorders

Target Name: SLC25A31

NCBI ID: G83447

SLC25A31

SLC25A31 Variant 1: Potential Therapeutic Target for Neurotransmitter Disorders

SLC25A31 (SLC25A31 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the SLC family of transport proteins, which are responsible for transmitting small molecules across cell membranes. SLC25A31 is characterized by its unique variant 1 sequence, which has been shown to alter its stability and function in the brain.

The SLC25A31 protein is involved in the transport of a variety of molecules, including neurotransmitters, hormones, and ions. It is expressed in the brain and other nervous tissue, and has been shown to play a role in the regulation of neurotransmitter release and synaptic plasticity.

SLC25A31 variants have been identified that differ in their sequence from the standard SLC25A31 protein. One of the most interesting of these variants is SLC25A31 variant 1, which has been shown to have altered stability and function in the brain.

SLC25A31 variant 1 has been shown to be expressed in the brain and other nervous tissue, and has been shown to play a role in the regulation of neurotransmitter release and synaptic plasticity. Studies have shown that SLC25A31 variant 1 is expressed at higher levels than the standard SLC25A31 protein in the brain, and that it is associated with increased levels of neurotransmitters such as dopamine and serotonin.

Additionally, SLC25A31 variant 1 has been shown to have altered function in the brain. Studies have shown that SLC25A31 variant 1 is involved in the regulation of neurotransmitter release and synaptic plasticity, and that it plays a role in the development of neurotransmitter-dependent plasticity.

These findings suggest that SLC25A31 variant 1 may be a drug target or biomarker for the treatment of neurotransmitter-related disorders. Further research is needed to fully understand the role of SLC25A31 variant 1 in the brain and the potential implications of targeting it for therapeutic purposes.

Protein Name: Solute Carrier Family 25 Member 31

Functions: ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (PubMed:15670820) (By similarity). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). Specifically required during spermatogenesis, probably to mediate ADP:ATP exchange in spermatocytes (PubMed:17137571). Large ATP supplies from mitochondria may be critical for normal progression of spermatogenesis during early stages of meiotic prophase I, including DNA double-strand break repair and chromosomal synapsis (By similarity). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity (By similarity). Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A31/ANT4 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Among nucleotides, may also exchange ADP for dATP and dADP (PubMed:15670820). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death (By similarity). It is however unclear if SLC25A31/ANT4 constitutes a pore-forming component of mPTP or regulates it (By similarity)

The "SLC25A31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets